Christopher Nevala-Plagemann

8PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 17, 2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

|Feb 26, 2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.

Manish A Shah, Erin B Kennedy, Dana Deighton

|Oct 25, 2024
Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'.

Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna

|Apr 25, 2024
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

Christopher Nevala-Plagemann, Ignacio Garrido-Laguna

|Jun 02, 2023
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.

Vaia Florou, Andrew Elliott, Matthew H Bailey

|Sep 23, 2021
Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.

Siddharth Iyengar, Christopher Nevala-Plagemann, Ignacio Garrido-Laguna

Pageof 2